Tin tức & Cập nhật

Chỉ hiển thị Multimedia
First-line biologic therapy persists longer than later agents in ankylosing spondylitis

First-line biologic therapy persists longer than later agents in ankylosing spondylitis

22 Feb 2022

Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.

First-line biologic therapy persists longer than later agents in ankylosing spondylitis

22 Feb 2022
NOACs preferable over warfarin in AF patients with bioprosthetic valves

NOACs preferable over warfarin in AF patients with bioprosthetic valves

22 Feb 2022
Why do some PCR-negative patients test positive on COVID-19 blood tests?

Why do some PCR-negative patients test positive on COVID-19 blood tests?

22 Feb 2022 bởiTristan Manalac

Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.

Why do some PCR-negative patients test positive on COVID-19 blood tests?

22 Feb 2022
Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH

Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH

21 Feb 2022 bởiAudrey Abella

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH

21 Feb 2022
Endometriosis tied to early natural menopause

Endometriosis tied to early natural menopause

21 Feb 2022
Antibody cocktail may help relieve burden from hospitals

Antibody cocktail may help relieve burden from hospitals

21 Feb 2022 bởiJairia Dela Cruz

Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.

Antibody cocktail may help relieve burden from hospitals

21 Feb 2022
Elevated dietary glycaemic index, load linked to higher CVD mortality risk

Elevated dietary glycaemic index, load linked to higher CVD mortality risk

21 Feb 2022